Stable production of anti-sickling adult hemoglobin (HBA T87Q) and elimination or significant reduction of vaso-occlusive events sustained through last follow-up for all evaluable patients (n=38), ...
The FDA approved two cell-based gene therapies, exagamglogene autotemcel (Casgevy) and lovotibeglogene autotemcel (Lyfgenia), for sickle cell disease (SCD), the agency announced. Marking the first FDA ...
Bluebird signs major coverage deal for sickle cell gene therapy Lyfgenia, easing some price concerns
Despite the high list price of Lyfgenia, bluebird has signed a large reimbursement deal for the sickle cell disease (SCD) gene therapy less than a week after its FDA approval. The outcomes-based ...
While bluebird bio reported details on the progress of its launch of three gene therapies on Tuesday, the Massachusetts biopharma also said it will have to refile its financial statements from 2022 ...
ELK GROVE VILLAGE, Ill., Feb. 26, 2026 /PRNewswire/ -- Orsini, a leader in rare disease pharmacy solutions, has been selected by Genetix Biotherapeutics Inc. as a specialty pharmacy partner for three ...
If you or someone you know has sickle cell disease (SCD), you may have heard of Lyfgenia, one of two gene therapies approved for this condition. Gene therapies are the only treatments for SCD that can ...
21 year old Sebastien Beauzile celebrates his Lyfgenia infusion with his medical team. Four months later, his doctors consider him cured from sickle cell anemia. A 21 year old man in New York has been ...
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “bluebird”) today announced the details of its U.S. commercial infrastructure to support timely, equitable ...
Gene therapy is offering new hope for people with sickle cell disease. Here's how Virginia's latest Medicaid funding could ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results